Loading stock data…
Dr. Reddy's Laboratories Ltd (RDY)
$11.88-0.09 (-0.75%)
Market ClosedLast close Sep 8
Dr.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dr. Reddy's Laboratories Limited in the Healthcare sector is trading at $11.88 with a market capitalization of $10.4B. Wall Street consensus targets $13.48 (5 analysts), implying a +13.5% move over the next 12 months. The stock is currently near its 52-week low of $11.36, remaining 11.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +13.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $80.70B↑ | $75.16B↓ | $87.27B↓ | $88.05B↑ | $85.45B |
| Gross Profit | $37.54B↓ | $43.03B↓ | $46.81B↓ | $48.14B↓ | $48.63B |
| Operating Income | $3.03B↑ | $829.00M↓ | $14.33B↓ | $17.87B↑ | $16.84B |
| Net Income | $4.43B↑ | $2.21B↓ | $12.10B↓ | $14.37B↑ | $14.18B |
Peer Comparison
JNJUNHPFE
Fundamentals
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Ac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.70%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.64%
Volume
Today's trading volume
2.13M
Recent News
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading
Asian equities traded in the US as American depositary receipts were tracking slightly higher Thursd
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Asian equities traded in the US as American depositary receipts were tracking higher Tuesday morning
Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Asian equities traded in the US as American depositary receipts started the week lower Monday mornin
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.